Halozyme Lifts Multi-Year Guidance on Royalty Surge and Strategic Acquisitions
Record Royalty Growth Bolsters New Revenue Targets for 2025–2026
Halozyme Therapeutics has updated investors with sharply higher preliminary 2025 revenue estimates, projecting total revenue of $1,385–$1,400 million. The standout detail: royalty revenue is expected to jump by 51%–52% year-over-year, reaching $865–$870 million—a signal of accelerating demand for the company’s ENHANZE-enabled products worldwide.
This update marks one of the company’s strongest guidance lifts yet. CEO Dr. Helen Torley highlighted ENHANZE’s growing influence and the recent addition of three new collaboration and licensing agreements. The approval of the 10th ENHANZE-based therapy, Rybrevant Faspro, further underscores this momentum.
| Metric | 2025 Estimate | Expected YoY Growth |
|---|---|---|
| Total Revenue | $1,385M – $1,400M | 36% – 38% |
| Royalty Revenue | $865M – $870M | 51% – 52% |
2026 Outlook: Upgraded Across All Key Financial Metrics
Looking ahead to 2026, Halozyme has set its sights even higher. The company now expects total revenue in the range of $1,710–$1,810 million—a stark increase from prior guidance and reflecting 23%–30% growth versus the new 2025 outlook. Royalty revenue, a central pillar of Halozyme’s business model, is projected to rise to $1,130–$1,170 million, a year-over-year gain of 30%–35% that is expected a full year earlier than previously forecasted.
On profitability, the company’s adjusted EBITDA and non-GAAP diluted EPS estimates have also been raised, factoring in $60 million of new strategic investments in their Hypercon and Surf Bio technology platforms.
| Metric | Previous Guidance | New Guidance | Expected YoY Growth |
|---|---|---|---|
| Total Revenue | $1,430M–$1,530M | $1,710M–$1,810M | 23%–30% |
| Royalty Revenue | $900M–$940M | $1,130M–$1,170M | 30%–35% |
| Adjusted EBITDA | $1,000M–$1,080M | $1,125M–$1,205M | - |
| Non-GAAP Diluted EPS | $6.50–$7.00 | $7.75–$8.25 | - |
Acquisition of Surf Bio Expands Drug Delivery Platform and Opportunity
In December 2025, Halozyme completed the acquisition of Surf Bio for up to $400 million, including an upfront payment of $300 million and potential milestones. Surf Bio brings its proprietary hyperconcentration technology, enabling high concentration delivery of biologics in a single auto-injector—expanding Halozyme’s drug delivery toolkit and extending the longevity of its intellectual property well into the mid-2040s.
The new technology promises to make the delivery of therapeutic antibodies and biologics more accessible for at-home or in-office care, potentially transforming patient experiences and reinforcing Halozyme’s competitive edge.
Broader Pipeline and Partnership Expansion Fuel Long-Term Confidence
Halozyme’s growth is firmly tied to its innovation pipeline and an increasingly diverse roster of global partners. The company projects having at least 15 partner programs in development and plans to add three or more new licensing agreements by 2026’s close.
With the addition of Surf Bio and ongoing adoption of ENHANZE, Halozyme aims to unlock durable revenue growth “well into the 2040s,” echoing its confidence in delivering long-run value for shareholders.
Key Takeaway: Royalty Engine and Technology Portfolio Set to Drive Sustained Value
Halozyme’s guidance raises and strategic investments highlight a business firing on all cylinders. The anticipated surge in royalty revenue and the expansion of its technology portfolio could make Halozyme a long-term growth story worth tracking, especially as the company presses its advantage in the evolving biopharma landscape.
The next landmark for investors to watch will be Halozyme’s investor call and further details on the integration of Surf Bio’s platform.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI